Establishing risk factors for bladder cancer to inform prevention: a pooled analysis of prospective studies from the NCI Cohort Consortium
The strongest and most established risk factors for bladder cancer are cigarette smoking, occupational exposure to carcinogens, and drinking water contaminants such as arsenic. The relative risk associated with smoking appears to have increased over the last 20 years for unknown reasons. Physical activity is associated with reduced risk.
Despite extensive research by many studies, it is unclear whether bladder cancer is related to other modifiable factors such as obesity, alcohol and coffee consumption, use of non-steroidal anti-inflammatory drugs (NSAIDs) and diet. Men have up to four times higher risk of bladder cancer than women, which is explained only in part by smoking and occupational exposures; reproductive and exogenous hormonal factors may therefore be important but have yet to be assessed prospectively with adequate power.
The NCI Cohort Consortium offers a unique opportunity to definitively assess associations with these largely modifiable risk factors using the largest sample size available globally.
Our objective is to pool data from several large prospective cohort studies to assess associations with bladder cancer risk for predominantly modifiable lifestyle factors for which findings to date have been inconclusive. Our specific aims are as follows:
Aim 1: to assess associations for smoking habits (over time), body size, alcohol consumption, other beverage consumption, consumption of fruit and vegetables, consumption of red and processed meats, dietary pattern, nutrient intake, use of aspirin and other NSAIDs, reproductive factors and exogenous hormone use
Aim 2: to assess the above associations by sex, smoking status and disease subtype
Neal Freedman; National Institute of Health; freedmanne@mail.nih.gov
Roger Milne; Cancer Council Victoria; Roger. Milne@cancervic.org.au
Nina Afshar; Cancer Council Victoria; Nina.Afshar@cancervic.org.au
Stephanie Smith-Warner; Harvard University; swarner@hsph.harvard.edu
Graham Giles; Cancer Council Victoria; Graham.Giles@cancervic.org.au
Dallas English; Cancer Council Victoria; d.english@unimelb.edu.au
Brigid Lynch; Cancer Council Victoria; brigid.lynch@cancervic.org.au
Debra Silverman; NIH National Cancer Institute; silvermd@mail.nih.gov
Nathaniel Rothman; NIH National Cancer Institute; rothmann@exchange.nih.gov
Alicja Wolk; Karolinska Institute; alicja.wolk@ki.se
Piet van den Brandt; Maastricht University; pa.vandenbrandt@maastrichtuniversity.nl